Biocon Limited: peers
Biocon Limited beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Belite Bio, Inc: the market cap on file is more than 60 days old or a last known value (no market-data feed for its exchange yet), so its valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Biocon Limitedbase BIOCON.BO · 🇮🇳 IN Percentile in Healthcare Percentile in India | Syngene International Limited SYNGENE.BO · 🇮🇳 IN Percentile in Healthcare Percentile in India | Belite Bio, Inc BLTE · 🇺🇸 US Percentile in Healthcare Percentile in USA | CG Oncology, Inc. CGON · 🇺🇸 US Percentile in Healthcare Percentile in USA | Oruka Therapeutics, Inc. ORKA · 🇺🇸 US Percentile in Healthcare Percentile in USA | Immunovant, Inc. IMVT · 🇺🇸 US Percentile in Healthcare Percentile in USA | Alkermes plc. ALKS · 🇮🇪 IE Percentile in Healthcare Percentile in Ireland | Rhythm Pharmaceuticals, Inc. RYTM · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $6.4 BNov 20, 2026 · Market data5th of 8 | $2.0 BNov 20, 2026 · Market data8th of 8 | $6.4 BAug 1, 2026 · Market data6th of 8 | $6.6 BSep 24, 2026 · Market data3rd of 8 | $6.5 BOct 28, 2026 · Market data4th of 8 | $6.6 BOct 7, 2026 · Market data2nd of 8 | $6.7 BOct 14, 2026 · Market data1st of 8 | $6.0 BOct 15, 2026 · Market data7th of 8 | $6.5 B8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | —— | —— | $4 MFY2025 · SEC3rd of 3 | —— | —— | $1.5 BFY2025 · SEC1st of 3 | $190 MFY2025 · SEC2nd of 3 | $190 M3 ranked |
| Net income (Higher is better) | —— | —— | $-78 MFY2025 · SEC2nd of 6 | $-161 MFY2025 · SEC4th of 6 | $-105 MFY2025 · SEC3rd of 6 | $-506 MFY2025 · SEC6th of 6 | $242 MFY2025 · SEC1st of 6 | $-197 MFY2025 · SEC5th of 6 | $-133 M6 ranked |
| Employees (Better neither way: ranked highest first) | 12,000As on 2020 · Profile1st of 8 | 6,148As on 2020 · Profile2nd of 8 | 41December 31, 2025 · Profile8th of 8 | 142December 31, 2025 · Profile5th of 8 | 68December 31, 2025 · Profile7th of 8 | 70As on 2021 · Profile6th of 8 | 2,050February 20, 2026 · Profile3rd of 8 | 414February 1, 2026 · Profile4th of 8 | 2788 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | ———— | ———— | ———— | +254.4%FY2025 · SEC1st of 397th98th | ———— | ———— | -5.3%FY2025 · SEC3rd of 318th9th | +45.8%FY2025 · SEC2nd of 383rd91st | +45.8%3 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | +9.9%FY2025 · SEC2nd of 253rd82nd | +100.2%FY2025 · SEC1st of 295th98th | +55.1%2 ranked |
| Earnings per share growth (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | -34.1%FY2025 · SEConly one with it14th21st | ———— | -34.1%— |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | 86.7%FY2025 · SEC2nd of 287th97th | 89.7%FY2025 · SEC1st of 292nd97th | 88.2%2 ranked |
| Operating margin (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | 17.2%FY2025 · SEC1st of 285th74th | -101.2%FY2025 · SEC2nd of 223rd10th | -42.0%2 ranked |
| Net margin (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | 16.4%FY2025 · SEC1st of 287th91st | -103.6%FY2025 · SEC2nd of 222nd9th | -43.6%2 ranked |
| Free cash flow margin (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | 32.5%FY2025 · SEC1st of 297th98th | -61.5%FY2025 · SEC2nd of 226th11th | -14.5%2 ranked |
| Return on equity (Higher is better) | ———— | ———— | -16.9%FY2025 · SEC2nd of 662nd29th | -21.7%FY2025 · SEC3rd of 660th27th | -24.7%FY2025 · SEC4th of 658th26th | -64.8%FY2025 · SEC5th of 636th15th | 14.7%FY2025 · SEC1st of 687th64th | -244.4%FY2025 · SEC6th of 67th3rd | -23.2%6 ranked |
| Return on invested capital (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | 14.7%FY2025 · SEConly one with it64th55th | ———— | 14.7%— |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | 153.9×price Nov 20, 2026 · Market data1st of 293rd95th | 35.1×price Nov 20, 2026 · Market data2nd of 255th53rd | ———— | ———— | ———— | ———— | ———— | ———— | 94.5×2 ranked |
| Price to sales (Better neither way: ranked highest first) | 3.5×price Nov 20, 2026 · Market data4th of 449th52nd | 5.1×price Nov 20, 2026 · Market data2nd of 457th62nd | ———— | ———— | ———— | ———— | 3.8×price Oct 14, 2026 · Market data3rd of 450th79th | 21.4×price Oct 15, 2026 · Market data1st of 484th94th | 4.4×4 ranked |
| Price to book (Better neither way: ranked highest first) | 1.6×price Nov 20, 2026 · Market data7th of 733rd18th | 4.5×price Nov 20, 2026 · Market data5th of 764th50th | 8.3׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 8.7×price Sep 24, 2026 · Market data3rd of 782nd88th | 13.8×price Oct 28, 2026 · Market data2nd of 789th93rd | 7.8×price Oct 7, 2026 · Market data4th of 779th86th | 3.7×price Oct 14, 2026 · Market data6th of 758th62nd | 43.2×price Oct 15, 2026 · Market data1st of 797th98th | 7.8×7 ranked |
| Free cash flow yield (Higher is better) | ———— | ———— | -0.6%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | -2.0%price Sep 24, 2026 · Market data4th of 562nd32nd | -1.4%price Oct 28, 2026 · Market data2nd of 564th34th | -6.1%price Oct 7, 2026 · Market data5th of 552nd25th | 7.2%price Oct 14, 2026 · Market data1st of 592nd62nd | -1.9%price Oct 15, 2026 · Market data3rd of 562nd32nd | -1.9%5 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | ———— | ———— | 0.0×FY2025 · SEC1st of 35th3rd | ———— | ———— | 0.0×FY2025 · SEC1st of 35th3rd | 0.7×FY2025 · SEC3rd of 366th56th | 0.0×3 ranked |
| Net debt to EBITDA (Lower is better) | ———— | ———— | ———— | ———— | ———— | ———— | -1.4×FY2025 · SEConly one with it11th5th | ———— | -1.4×— |
| Piotroski F-score (Higher is better) | —— | —— | —— | —— | —— | —— | —— | 6 of 9FY2025 · SEConly one with it | 6.0 of 9— |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | —— | 1 of 8FY2025 · Scorecard4th of 6 | 4 of 13FY2025 · Scorecard3rd of 6 | 1 of 10FY2025 · Scorecard5th of 6 | 1 of 12FY2025 · Scorecard6th of 6 | 15 of 24FY2025 · Scorecard1st of 6 | 7 of 20FY2025 · Scorecard2nd of 6 | 22% passed6 ranked |
| Valuation checks (Higher is better) | —— | —— | —— | 0 of 4FY2025 · Scorecard2nd of 5 | 0 of 4FY2025 · Scorecard2nd of 5 | 0 of 4FY2025 · Scorecard2nd of 5 | 3 of 6FY2025 · Scorecard1st of 5 | 0 of 5FY2025 · Scorecard2nd of 5 | 0% passed5 ranked |
| Growth checks (Higher is better) | —— | —— | 0 of 2FY2025 · Scorecard4th of 6 | 1 of 2FY2025 · Scorecard2nd of 6 | 0 of 1FY2025 · Scorecard4th of 6 | 0 of 2FY2025 · Scorecard4th of 6 | 2 of 6FY2025 · Scorecard3rd of 6 | 3 of 5FY2025 · Scorecard1st of 6 | 17% passed6 ranked |
| Profitability checks (Higher is better) | —— | —— | 0 of 3FY2025 · Scorecard3rd of 6 | 0 of 2FY2025 · Scorecard3rd of 6 | 0 of 3FY2025 · Scorecard3rd of 6 | 0 of 3FY2025 · Scorecard3rd of 6 | 4 of 6FY2025 · Scorecard1st of 6 | 1 of 5FY2025 · Scorecard2nd of 6 | 0% passed6 ranked |
| Financial health checks (Higher is better) | —— | —— | 1 of 2FY2025 · Scorecard4th of 6 | 3 of 4FY2025 · Scorecard2nd of 6 | 1 of 2FY2025 · Scorecard4th of 6 | 1 of 2FY2025 · Scorecard4th of 6 | 5 of 5FY2025 · Scorecard1st of 6 | 3 of 4FY2025 · Scorecard2nd of 6 | 63% passed6 ranked |
| Shareholder returns checks (Higher is better) | —— | —— | 0 of 1FY2025 · Scorecard2nd of 5 | 0 of 1FY2025 · Scorecard2nd of 5 | —— | 0 of 1FY2025 · Scorecard2nd of 5 | 1 of 1FY2025 · Scorecard1st of 5 | 0 of 1FY2025 · Scorecard2nd of 5 | 0% passed5 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | —— | 23.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 6 | 104.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 6 | 113.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 6 | 52.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 6 | 104.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 6 | 114.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 6 | 104.2%6 ranked |
| Institutions holding (Better neither way: ranked highest first) | —— | —— | 962026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 6 | 2332026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 6 | 2592026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 6 | 2322026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 6 | 4162026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 6 | 3332026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 6 | 2466 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | —— | —— | +1.2 pp2026-Q2 against 2026-Q1 · 13F3rd of 5 | +24.3 pp2026-Q2 against 2026-Q1 · 13F1st of 5 | -0.8 pp2026-Q2 against 2026-Q1 · 13F5th of 5 | +0.7 pp2026-Q2 against 2026-Q1 · 13F4th of 5 | +5.1 pp2026-Q2 against 2026-Q1 · 13F2nd of 5 | +1.2 pp5 ranked |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Biocon Limited: National Stock Exchange of India, daily market-cap file; Syngene International Limited: National Stock Exchange of India, daily market-cap file; Belite Bio, Inc: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; CG Oncology, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Oruka Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Immunovant, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Alkermes plc.: How market caps are worked out; Rhythm Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Biocon Limited | — | — | — |
| Syngene International Limited | — | — | — |
| Belite Bio, Inc | — | — | — |
| CG Oncology, Inc. | — | — | — |
| Oruka Therapeutics, Inc. | — | — | — |
| Immunovant, Inc. | — | — | — |
| Alkermes plc. | 17.2%FY2025 | 85th percentile in Healthcaremedian -8.0%, 684 companies | 74th percentile in Irelandmedian 9.3%, 25 companies |
| Rhythm Pharmaceuticals, Inc. | -101.2%FY2025 | 23rd percentile in Healthcaremedian -8.0%, 684 companies | 10th percentile in USAmedian 3.5%, 2,595 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Biocon Limited | Syngene International Limited | Belite Bio, Inc | CG Oncology, Inc. | Oruka Therapeutics, Inc. | Immunovant, Inc. | Alkermes plc. | Rhythm Pharmaceuticals, Inc. |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | — | — | $4 MSEC3rd | — | — | $1.5 BSEC1st | $190 MSEC2nd |
| 2024 | — | — | — | $1 MSEC3rd | — | — | $1.6 BSEC1st | $130 MSEC2nd |
| 2023 | — | — | — | $0 MSEC3rd | — | — | $1.7 BSEC1st | $77 MSEC2nd |
| 2022 | — | — | — | — | — | — | $1.1 BSEC1st | $24 MSEC2nd |
| 2021 | — | — | — | — | — | — | $1.2 BSEC1st | $3 MSEC2nd |
| 2020 | — | — | — | — | — | — | $1.0 BSEC | — |
| 2019 | — | — | — | — | — | — | $1.2 BSEC | — |
| 2018 | — | — | — | — | — | — | $1.1 BSEC | — |
| 2017 | — | — | — | — | — | — | $903 MSEC | — |
| 2016 | — | — | — | — | — | — | $746 MSEC | — |
| 2015 | — | — | — | — | — | — | $628 MSEC | — |
| 2014 | — | — | — | — | — | — | $619 MSEC | — |
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Biocon Limited#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Syngene International LimitedSYNGENE.BO · 🇮🇳 IndiaSame industry: Biotechnology · Similar size: $2.0 B market cap against $6.4 B · Same country: IndiaMarket cap $2.0 B (Nov 20, 2026) · revenue $388 M (year to March 2023)87 of 100 (industry or sector 50 + size 22 + country 15)In the group
- Belite Bio, IncBLTE · 🇺🇸 USASame industry: Biotechnology · Similar size: $6.4 B market cap against $6.4 B · Ratios of the last two fiscal years on fileMarket cap $6.4 B (Aug 1, 2026)85 of 100 (industry or sector 50 + size 30 + figures on file 5)In the group
- CG Oncology, Inc.CGON · 🇺🇸 USASame industry: Biotechnology · Similar size: $6.6 B market cap against $6.4 B · Ratios of the last two fiscal years on fileMarket cap $6.6 B (Sep 24, 2026) · revenue $4 M (year to December 2025)85 of 100 (industry or sector 50 + size 30 + figures on file 5)In the group
- Oruka Therapeutics, Inc.ORKA · 🇺🇸 USASame industry: Biotechnology · Similar size: $6.5 B market cap against $6.4 B · Ratios of the last two fiscal years on fileMarket cap $6.5 B (Oct 28, 2026)85 of 100 (industry or sector 50 + size 30 + figures on file 5)In the group
- Immunovant, Inc.IMVT · 🇺🇸 USASame industry: Biotechnology · Similar size: $6.6 B market cap against $6.4 B · Ratios of the last two fiscal years on fileMarket cap $6.6 B (Oct 7, 2026)85 of 100 (industry or sector 50 + size 30 + figures on file 5)In the group
- Alkermes plc.ALKS · 🇮🇪 IrelandSame industry: Biotechnology · Similar size: $6.7 B market cap against $6.4 B · Ratios of the last two fiscal years on fileMarket cap $6.7 B (Oct 14, 2026) · revenue $1.5 B (year to December 2025)85 of 100 (industry or sector 50 + size 30 + figures on file 5)In the group
- Rhythm Pharmaceuticals, Inc.RYTM · 🇺🇸 USASame industry: Biotechnology · Similar size: $6.0 B market cap against $6.4 B · Ratios of the last two fiscal years on fileMarket cap $6.0 B (Oct 15, 2026) · revenue $190 M (year to December 2025)85 of 100 (industry or sector 50 + size 30 + figures on file 5)In the group
- Ligand Pharmaceuticals IncorporatedLGND · 🇺🇸 USASame industry: Biotechnology · Similar size: $5.9 B market cap against $6.4 B · Ratios of the last two fiscal years on fileMarket cap $5.9 B (Oct 20, 2026) · revenue $268 M (year to December 2025)84 of 100 (industry or sector 50 + size 30 + figures on file 5)+ Add
- Ionis Pharmaceuticals, Inc.IONS · 🇺🇸 USASame industry: Biotechnology · Similar size: $7.1 B market cap against $6.4 B · Ratios of the last two fiscal years on fileMarket cap $7.1 B (Oct 26, 2026) · revenue $944 M (year to December 2025)84 of 100 (industry or sector 50 + size 29 + figures on file 5)+ Add
- Kodiak Sciences Inc.KOD · 🇺🇸 USASame industry: Biotechnology · Similar size: $5.7 B market cap against $6.4 B · Ratios of the last two fiscal years on fileMarket cap $5.7 B (Oct 22, 2026)84 of 100 (industry or sector 50 + size 29 + figures on file 5)+ Add
- Kiniksa Pharmaceuticals, Ltd.KNSA · 🇧🇲 BermudaSame industry: Biotechnology · Similar size: $7.5 B market cap against $6.4 B · Ratios of the last two fiscal years on fileMarket cap $7.5 B (Oct 29, 2026) · revenue $678 M (year to December 2025)84 of 100 (industry or sector 50 + size 29 + figures on file 5)+ Add
- Cogent Biosciences, Inc.COGT · 🇺🇸 USASame industry: Biotechnology · Similar size: $5.5 B market cap against $6.4 B · Ratios of the last two fiscal years on fileMarket cap $5.5 B (Oct 22, 2026)84 of 100 (industry or sector 50 + size 29 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.